



« Tailor-made » stenting solution


APPAC - 2018

Diagnostic




Stratégie

Diamètre nominal du stent [mm]		Longueur nominale du stent [mm]	Longueur distale du stent	Longueur proximale du stent
Dist	Prox			
2,50	3,00	16	55%	37%
2,50	3,25	16	55%	37%
2,75	3,50	16	55%	37%
3,00	3,50	16	56%	36%
3,00	3,75	16	54%	38%
3,50	4,25	16	54%	38%
3,75	4,50	16	56%	37%
2,50	3,00	19	54%	39%
2,50	3,25	19	54%	39%
2,75	3,50	19	54%	39%
3,00	3,50	19	55%	38%
3,00	3,75	19	54%	40%
3,50	4,25	19	54%	40%
3,75	4,50	19	55%	39%
2,50	3,00	24	56%	38%
2,50	3,25	24	56%	38%
2,75	3,50	24	56%	38%
3,00	3,50	24	57%	37%
3,00	3,75	24	56%	39%
3,50	4,25	24	56%	39%
3,75	4,50	24	57%	38%




	BIOSS Lim C
Stent material	L605
Immunosuppressive drug	SIROLIMUS
Polymer	BIODEGRADABLE
Wall thickness	0,07 mm
Compatible with guide wire	max. .014"
Compatible with guiding catheter	5F
Crimped stent profile	.038" (0,96 mm)
Nominal pressure	10 atm
RBP	16 atm
Catheter length	140 cm
Delivery system type	RX

Angioplastie




Angioplastie




TLR – Resténose ?

	BiOSS group n=102 (%)		rDES group n=100 (%)	
	30 days	12 mo	30 days	12 mo
MACE	2 (1.9)	12 (11.8)	2 (2)	15 (15)
All-cause death	0	1 (1)	0	3 (3)
Cardiac death	0	0	0	3 (3)
MI	1 (1)	2 (1.9)	1 (1)	3 (3)
Definite ST	1 (1)	1 (1)	1 (1)	1 (1)
Cumulative TLR	1 (1)	10 (9.8)	1 (1)	9 (9)
Clinically driven TLR	1 (1)	5 (4.9)	1 (1)	3 (3)
TVR	1 (1)	14 (13.7)	1 (1)	12 (12)
PCI in another vessel	0	8 (7.8)	0	6 (6)
MACE: major adverse cardiovascular events; MI: myocardial infarction; PCI: percutaneous coronary intervention; rDES: regular drug-eluting stent; ST: stent thrombosis; TLR: target lesion revascularisation; TVR: target vessel revascularisation				

Tips and Tricks



Tips and Tricks



Take home message

